Carmen Hollield, Shivkar Amara, Jesse M Lewin, Mark G Lebwohl
{"title":"Neoadjuvant Sonidegib for the Management of Locally Advanced Basal Cell Carcinoma: A Case Report.","authors":"Carmen Hollield, Shivkar Amara, Jesse M Lewin, Mark G Lebwohl","doi":"10.36849/JDD.8329","DOIUrl":null,"url":null,"abstract":"<p><p>Neoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the tolerability of HPI therapy may be limited due to adverse effects (muscle spasms, alopecia). However, studies have shown a lower incidence of side effects with sonidegib, compared to vismodegib. In this report, we present the case of an 86-year-old male with laBCC on the left inner canthus treated successfully with neoadjuvant sonidegib for 25 weeks prior to Mohs micrographic surgery. This case highlights the utility of sonidegib as a potential neoadjuvant treatment modality for patients who are good candidates for surgery but would benefit from tumor reduction to achieve a more favorable outcome, especially in cosmetically sensitive areas. In addition, our patient experienced minimal side effects (muscle cramps at week 18) from sonidegib treatment. J Drugs Dermatol. 2025;24(3):329-331. doi:10.36849/JDD.8329.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"329-331"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8329","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Neoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the tolerability of HPI therapy may be limited due to adverse effects (muscle spasms, alopecia). However, studies have shown a lower incidence of side effects with sonidegib, compared to vismodegib. In this report, we present the case of an 86-year-old male with laBCC on the left inner canthus treated successfully with neoadjuvant sonidegib for 25 weeks prior to Mohs micrographic surgery. This case highlights the utility of sonidegib as a potential neoadjuvant treatment modality for patients who are good candidates for surgery but would benefit from tumor reduction to achieve a more favorable outcome, especially in cosmetically sensitive areas. In addition, our patient experienced minimal side effects (muscle cramps at week 18) from sonidegib treatment. J Drugs Dermatol. 2025;24(3):329-331. doi:10.36849/JDD.8329.
期刊介绍：
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
